highmark glp-1 coverage BCBSM pulling back on Highmark Blue Cross Blue Shield

The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity

38 DeaconC

This article starts with the confirmed Supplement Facts label because that's where the real story is

Patients who are borderline diabetic, have significant excess fat or carry increased cardiovascular risk may need standard-dose GLP-1 therapy

All procedures were approved by the University of Pennsylvania Institutional Animal Care and Use Committee and conform to the NIH Guide for the Care and Use of Laboratory Animals